HBSP (USA)
-
The Tavistock Group and the Australian Agricultural Company
Roscini, Dante; Preble, MatthewCase HBS-717009-EEconomicsIn late 2015, Dr. Shehan Dissanayake, a managing director and board member of the Bahamian-based investment firm The Tavistock Group (Tavistock), the largest single shareholder in the Australian Agricultural Company (AACo), one of the country's largest agribusinesses, faces a potentially challenging future operating environment in Australia. The country's national government has recently instituted changes to its agricultural foreign direct inves...Starting at €8.20
-
The Rise of Populism and Italy's Electoral "Tsunami"
Abdelal, Rawi; Roscini, Dante; Corsi, ElenaCase HBS-719042-EEconomicsThe case explores several reasons behind the rise of populism in Italy and ponders the long-term sustainability of populist governments. Italy's March 2018 elections led to a populist government which included the right-wing League and the anti-establishment 5 Star Movement. To respect their electoral promises, the two parties came up with a budget plan which provided for a public deficit at 2.4%, a figure higher than what the previous administra...Starting at €8.20
-
Viva Macau (A) and (B), Teaching Note
Roscini, DanteTeaching Note HBS-717024-EEconomicsTeaching Note for cases 714024 and 714025.Starting at €0.00
-
Viva Macau (A)
Roscini, Dante; Donovan, G.A.Case HBS-714024-EEconomicsA fast-growing Macau-based airline backed by private US investors faces a dramatic expropriation in the wake of the first change of head of government since the former Portuguese colony became a Special Administrative Region of China. The case allows students to explore what Foreign Direct Investors can do to foresee a possible expropriation event and what options they might consider to protect themselves ex-ante or fight the outcome ex-post.Starting at €8.20
-
GlaxoSmithKline in China (A)
Quelch, John A.; Rodriguez, MargaretCase HBS-514049-EMarketingFour GlaxoSmithKline employees were accused of bribing Chinese health care workers to prescribe the company's drugs. The accusations brought to light the questionable incentive structures of the Chinese health care system and the pressure on companies to adhere to local customs while still observing local laws.Starting at €8.20
-
GlaxoSmithKline in China (B)
Quelch, John A.; Rodriguez, MargaretCase HBS-514050-EMarketingIn 2013, Chinese investigators detained four GSK employees for allegedly bribing health care staff to sell GSK pharmaceuticals. A month later, GSK's Asia Pacific regional president, Abbas Hussain, said the company would help identify corrupt practices. Two days later, GSK's CEO, Andrew Witty, called the allegations "shameful" and said the company would use the opportunity to "make changes."Starting at €5.74
-
GlaxoSmithKline in China (C)
Quelch, John A.; Rodriguez, MargaretCase HBS-514092-EMarketingThis case is a follow up to GlaxoSmithKline (A), 514049 and GlaxoSmithKline (B), 514050.Starting at €5.74
-